Literature DB >> 31085720

Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint Inhibitors.

Changhua Ji1, Marc D Roy2, Jonathan Golas3, Allison Vitsky4, Sripad Ram5, Steven W Kumpf2, Matthew Martin2, Frank Barletta6, William A Meier7, Andrea T Hooper3, Puja Sapra3, Nasir K Khan8, Martin Finkelstein9, Magali Guffroy10, Bernard S Buetow5.   

Abstract

PURPOSE: Immune checkpoint inhibitors (ICI) targeting PD1, PDL1, or CTLA4 are associated with immune-related adverse events (irAE) in multiple organ systems including myocarditis. The pathogenesis and early diagnostic markers for ICI-induced myocarditis are poorly understood, and there is currently a lack of laboratory animal model to enhance our understanding. We aimed to develop such a model using cynomolgus monkeys. EXPERIMENTAL
DESIGN: Chinese-origin cynomolgus monkeys were dosed intravenously with vehicle or nivolumab 20 mg/kg plus ipilimumab 15 mg/kg once weekly and euthanized on day 29.
RESULTS: Multiple organ toxicities were observed in cynomolgus monkeys, and were characterized by loose feces, lymphadenopathy, and mononuclear cell infiltrations of varying severity in heart, colon, kidneys, liver, salivary glands, and endocrine organs. Increased proliferation of CD4+ and CD8+ T lymphocytes as well as an increase in activated T cells and central memory T cells in the blood, spleen, and lymph nodes, were observed. Transcriptomic analysis suggested increased migration and activation of T cells and increased phagocytosis and antigen presentation in the heart. Mononuclear cell infiltration in myocardium was comprised primarily of T cells, with lower numbers of macrophages and occasional B cells, and was associated with minimal cardiomyocyte degeneration as well as increases in cardiac troponin-I and NT-pro-BNP. Morphologically, cardiac lesions in our monkey model are similar to the reported ICI myocarditis in humans.
CONCLUSIONS: We have developed a monkey model characterized by multiple organ toxicities including myocarditis. This model may provide insight into the immune mechanisms and facilitate biomarker identification for ICI-associated irAEs. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 31085720     DOI: 10.1158/1078-0432.CCR-18-4083

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  25 in total

Review 1.  Cardiac Remodelling Following Cancer Therapy: A Review.

Authors:  Tan Panpan; Du Yuchen; Shi Xianyong; Liu Meng; He Ruijuan; Dong Ranran; Zhang Pengyan; Li Mingxi; Xie Rongrong
Journal:  Cardiovasc Toxicol       Date:  2022-07-25       Impact factor: 2.755

Review 2.  Preparation and Evaluation of Animal Models of Cardiotoxicity in Antineoplastic Therapy.

Authors:  Chenchen Meng; Lu Fan; Xiaoming Wang; Yunjiao Wang; Yanyang Li; Shuchao Pang; Shichao Lv; Junping Zhang
Journal:  Oxid Med Cell Longev       Date:  2022-07-05       Impact factor: 7.310

3.  Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy.

Authors:  Francesca Castagnoli; Simon Doran; Jason Lunn; Anna Minchom; Mary O'Brien; Sanjay Popat; Christina Messiou; Dow-Mu Koh
Journal:  PLoS One       Date:  2022-07-07       Impact factor: 3.752

Review 4.  Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies.

Authors:  Daniel Ronen; Aseel Bsoul; Michal Lotem; Suzan Abedat; Merav Yarkoni; Offer Amir; Rabea Asleh
Journal:  Vaccines (Basel)       Date:  2022-03-31

5.  Cardiovascular Outcomes in the Patients With Colorectal Cancer: A Multi-Registry-Based Cohort Study of 197,699 Cases in the Real World.

Authors:  Shilong Zhang; Yan Wang; Pengfei Zhang; Luoyan Ai; Tianshu Liu
Journal:  Front Cardiovasc Med       Date:  2022-06-16

Review 6.  The foundations of immune checkpoint blockade and the ipilimumab approval decennial.

Authors:  Alan J Korman; Sarah C Garrett-Thomson; Nils Lonberg
Journal:  Nat Rev Drug Discov       Date:  2021-12-22       Impact factor: 112.288

Review 7.  PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism.

Authors:  Hao Dong; Yihang Qi; Xiangyi Kong; Zhongzhao Wang; Yi Fang; Jing Wang
Journal:  Front Pharmacol       Date:  2022-04-19       Impact factor: 5.988

Review 8.  Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer.

Authors:  Pilar Martín; Rafael Blanco-Domínguez; Raquel Sánchez-Díaz
Journal:  Cell Mol Immunol       Date:  2020-11-24       Impact factor: 11.530

Review 9.  Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.

Authors:  Alan H Baik; Katy K Tsai; David Y Oh; Mandar A Aras
Journal:  Clin Sci (Lond)       Date:  2021-03-12       Impact factor: 6.124

Review 10.  Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment.

Authors:  Nicolas Palaskas; Juan Lopez-Mattei; Jean Bernard Durand; Cezar Iliescu; Anita Deswal
Journal:  J Am Heart Assoc       Date:  2020-01-21       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.